We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Semaglutide (GLP-1 receptor agonist)
An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended.
Prescription medication — not a dietary supplement
Semaglutide is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Semaglutide doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2016–2026 with a typical study size of 803 participants.
Based on 455 studies · 134 meta-analyses · 243 RCTs · 6,228 total participants
Confidence
High confidenceBy outcome
An FDA-approved drug with one of the strongest evidence bases here: multiple large phase-3 RCTs (STEP, SUSTAIN, SELECT) prove substantial weight loss, glycemic control, and reduced cardiovascular events.
278 randomised trials
90% were about Semaglutide in an audit of 50 of them
Every randomised or controlled trial of Semaglutide indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
372 trials ongoing or recruiting · 353 completed on ClinicalTrials.gov
106 of the completed trials have posted results
Registered trials show research momentum for Semaglutide, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Semaglutide is a long-acting analogue of the gut hormone GLP-1 (glucagon-like peptide-1).
It is a prescription drug, NOT a dietary supplement: branded as Ozempic (subcutaneous, type 2 diabetes), Rybelsus (oral, type 2 diabetes), and Wegovy (subcutaneous, chronic weight management), with US FDA and EU approvals that depend on the brand, formulation and indication.
Check the current label for the exact product; do not transfer a cardiovascular indication from one product to another. Mechanistically it activates the GLP-1 receptor in the pancreas (glucose-dependent insulin secretion, suppressed glucagon), brain (appetite suppression and satiety), and gut (slowed gastric emptying).
The evidence base is one of the strongest of any compound described here: multiple large phase-3 randomized controlled trials.
In type 2 diabetes, SUSTAIN-6 (3,297 patients) showed a 26% relative reduction in major adverse cardiovascular events (HR 0.74) and head-to-head SUSTAIN 7 beat dulaglutide on both HbA1c and weight.
For weight management, STEP 1 (1,961 adults without diabetes) produced a mean −14.9% body-weight change vs −2.4% on placebo at 68 weeks, with over half losing ≥15%; STEP 8 showed it substantially out-loses liraglutide.
SELECT (17,604 patients with cardiovascular disease and overweight/obesity but WITHOUT diabetes) showed a 20% relative reduction in cardiovascular death, MI, or stroke (HR 0.80). Oral semaglutide (PIONEER program) reproduces glycemic benefit and was cardiovascular-non-inferior in PIONEER 6.
In the US, FDA labeling for semaglutide carries a boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma) and under that US label is contraindicated with a personal/family history of medullary thyroid carcinoma or MEN2; it carries risks of pancreatitis, gallbladder disease, and ileus; gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common; weight loss includes loss of lean muscle; and the FDA has warned about dosing errors and impurities in compounded/grey-market semaglutide.
It should be used only under a clinician's care, for a genuine medical indication — not as a cosmetic shortcut.
A long-acting analogue of the incretin hormone GLP-1 that binds and activates the GLP-1 receptor in the pancreas, brain, and gastrointestinal tract — the single upstream target driving all downstream effects.
Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner and suppresses glucagon, lowering blood glucose and HbA1c with low intrinsic hypoglycemia risk.
Acts on central appetite-regulating circuits to increase satiety and reduce food intake, the primary driver of the substantial weight loss seen in the STEP trials.
Delays gastric emptying, blunting post-meal glucose excursions and prolonging fullness — and the mechanism behind much of the nausea and the ileus signal.
How Semaglutide works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Contraindicated — under the US label, which carries a US FDA boxed warning for thyroid C-cell tumors. In Germany or Austria, the current product information for the exact medicine applies.
Use with caution under specialist guidance; generally avoid with prior pancreatitis.
Contraindicated — discontinue at least 2 months before a planned pregnancy.
Not appropriate — this is a prescription drug with real risks, not a cosmetic shortcut. Use only for a clinician-confirmed indication.
Combining with insulin or sulfonylureas raises hypoglycemia risk; the clinician typically reduces those agents. Semaglutide alone is low-hypoglycemia (glucose-dependent action).
Delayed gastric emptying can change the absorption of co-administered oral drugs; clinician monitoring advised, especially for narrow-therapeutic-index medicines.
Do not combine with another GLP-1 agonist (e.g. liraglutide, dulaglutide, tirzepatide) — additive risk with no added benefit.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Contact your treating team about the symptom and follow the product-specific instructions. Do not reduce, split, stop or restart prescribed treatment solely to continue this experiment.
Tip: Seek care for upper-right abdominal pain, fever, or jaundice
Tip: Discontinue and seek urgent care for severe, persistent abdominal pain radiating to the back
Tip: Post-marketing reports; seek care for severe constipation, bloating, or inability to pass stool/gas
Tip: Resistance training and adequate protein intake during weight loss
Tip: Linked to rapid glucose lowering (SUSTAIN-6); patients with diabetic retinopathy need ophthalmologic monitoring
Semaglutide has an evidence score of 8.5/10 — very strong evidence based on 455 indexed studies, including 2 meta-analyses. An FDA-approved GLP-1 receptor agonist (Ozempic/Rybelsus for type 2 diabetes, Wegovy for chronic weight management) with genuinely strong, large-RCT evidence for glycemic control and substantial weight loss, plus a cardiovascular-outcomes benefit. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and growing concern about grey-market/compounded versions. It is a prescription drug, not a supplement, and is never auto-recommended. Representative study: PMID 34047443.
Dosing for Semaglutide: Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Semaglutide — consistent daily use matters more than the time of day. Subcutaneous dosing is once weekly on the same day, with or without food.
Semaglutide should be used with caution — talk to a healthcare provider before taking it. Reported side effects include acute pancreatitis, ileus / severe GI motility problems, gallbladder disease (cholelithiasis / cholecystitis). How often they occur is not established for all of them. Use caution if any of these apply to you: Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label); Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label); Prior serious hypersensitivity to semaglutide or any GLP-1 receptor agonist.
Tirzepatide
Too few graded studiesAn FDA-approved prescription medication (Mounjaro for type 2 diabetes, Zepbound for obesity and obstructive sleep apnea), not a dietary supplement. Honest appraisal: in head-to-head phase-3 trials it is the most effective approved weight-loss drug to date — up to ~21% body-weight loss over 72 weeks and superior to semaglutide — but it is a real medicine with real risks: a US FDA boxed warning for thyroid C-cell tumors, common GI side effects, and pancreatitis/gallbladder signals. Do not source or use it outside a prescription.
Liraglutide
Too few graded studiesAn FDA-approved, once-daily GLP-1 receptor agonist (Victoza for type 2 diabetes, Saxenda for chronic weight management). Honest appraisal: a real prescription medicine with genuinely strong large-RCT evidence for glycemic control and moderate weight loss, plus a cardiovascular-outcomes benefit (LEADER). It also carries real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and lean-mass loss with weight loss. It is a prescription medicine, NOT a supplement, and is not auto-recommended.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism. Its only head-to-head trial with metformin cited here was a 36-person pilot, which does not show it can replace metformin.
Dulaglutide
Too few graded studiesAn FDA-approved once-weekly GLP-1 receptor agonist (brand Trulicity) for type 2 diabetes, with genuinely strong, large-RCT evidence for lowering HbA1c plus a dedicated cardiovascular-outcomes trial (REWIND) showing a ~12% reduction in major cardiovascular events. Honest appraisal: this is a real prescription medicine with real efficacy AND real risks — a US FDA boxed warning for thyroid C-cell tumors, pancreatitis and gallbladder risk, very common GI side effects, and modest (not semaglutide-tier) weight loss. It is a prescription drug, not a supplement, and is never auto-recommended.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 455 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research